Impact of Adalimumab on Symptoms of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A Pooled Analysis of Randomized Clinical Trials
Authors:
Open Access
- 19 November 2009
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 220 (1) , 1-7
Abstract
Background: Psoriatic arthritis often affects patients with psoriasis. Objective: To examine the effect of adalimumab on psoriatic arthritis in patients with moderate to severe psoriasis. Methods: Data from patients with psoriasis and a reported history of comorbid psoriatic arthritis in 3 randomized, placebo-controlled psoriasis trials of adalimumab were analyzed. Results: Adalimumab (n = 274) reduced the risk of psoriatic arthropathy adverse events by 75% versus placebo (1.1 vs. 4.8%; p = 0.025). Psoriasis/psoriatic arthritis-related pain was significantly reduced (–31.3 vs. –5.6 visual analog scale units; p < 0.0001). At week 16, adalimumab-treated patients were more likely to respond (56.9 vs. 4.5%; p < 0.001) and responded for a greater percentage of follow-up time (39.3 vs. 2.9%; p< 0.0001) than placebo-treated patients (regression model for PASI 75 and ACR 20 responses). Conclusion: Adalimumab treatment of moderate to severe psoriasis reduced symptoms of comorbid psoriatic arthritis.Keywords
This publication has 18 references indexed in Scilit:
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- Impact of adalimumab treatment on patient‐reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisJournal of Dermatological Treatment, 2007
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006
- Epidemiology of psoriatic arthritis in the population of the United StatesJournal of the American Academy of Dermatology, 2005
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- A clinician's paradigm in the treatment of psoriasisJournal of the American Academy of Dermatology, 2005
- Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risksBritish Journal of Dermatology, 2005
- Quality of life issues in psoriasisJournal of the American Academy of Dermatology, 2003
- The Statistical Evaluation of Medical Tests for Classification and Prediction2003
- The direct cost of care for psoriasis and psoriatic arthritis in the United StatesJournal of the American Academy of Dermatology, 2002